ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (Gleevec), a well-known FDA-approved BCR-ABL fusion protein inhibitor for treatment of Philadelphia chromosome positive chronic myelogenous leukemia (CML), targets the tyrosine kinase domain on the ABL side56.